Litigation Details for Alza Corporation v. Impax Laboratories Inc. (D. Del. 2005)

Alza Corporation v. Impax Laboratories Inc. (D. Del. 2005)

Docket		Date Filed	2005-09-01
Court	District Court, D. Delaware	Date Terminated	2009-05-06
Cause	35:271 Patent Infringement	Assigned To	Joseph James Farnan Jr.
Jury Demand		Referred To
Parties	IMPAX LABORATORIES INC.
Patents	6,919,373; 8,445,013
Link to Docket	External link to docket

Details for Alza Corporation v. Impax Laboratories Inc. (D. Del. 2005)

Date Filed	Document No.	Description	Snippet	Link To Document
2005-09-01				External link to document

Alza Corporation v. Impax Laboratories: Litigation Summary, Patent Analysis, and Generic Entry Impact

Last updated: August 4, 2026

Alza Corporation v. Impax Laboratories, Inc., No. 1:05-cv-00642, was a Hatch-Waxman patent dispute involving Impax's abbreviated new drug application for a generic version of Concerta, an extended-release methylphenidate hydrochloride product. The case centered on U.S. Patent No. 6,919,373, which covered aspects of Alza's osmotic extended-release delivery system. The Federal Circuit affirmed the determination that the asserted claims were invalid for obviousness, removing the principal patent barrier to Impax's generic product. Alza Corp. v. Impax Labs., Inc., 603 F.3d 935 (Fed. Cir. 2010).

What drug and patent were involved in Alza v. Impax?

The dispute involved Concerta, an extended-release oral formulation of methylphenidate hydrochloride used to treat attention-deficit/hyperactivity disorder.

Item	Detail
Brand product	Concerta
Active ingredient	Methylphenidate hydrochloride
Dosage form	Extended-release tablet
Regulatory pathway	Impax ANDA
Plaintiff	Alza Corporation
Defendant	Impax Laboratories, Inc.
District court	U.S. District Court for the District of Delaware
Case number	1:05-cv-00642
Principal patent	U.S. Patent No. 6,919,373
Federal Circuit citation	603 F.3d 935
Core issue	Obviousness of extended-release osmotic delivery claims
Final appellate result	Affirmed invalidity judgment

Concerta used an osmotic delivery platform designed to release methylphenidate over an extended period. The '373 patent addressed formulation and delivery characteristics that controlled the timing and rate of drug release.

What patents protected Concerta in the Alza Impax litigation?

The central patent in the reported appellate decision was U.S. Patent No. 6,919,373. The patent was assigned to Alza and claimed an osmotic drug-delivery system for methylphenidate formulations.

The litigation occurred within a broader Concerta patent estate that included earlier patents directed to controlled-release methylphenidate technology. The asserted claims in the Impax case were evaluated primarily under 35 U.S.C. § 103, which governs obviousness.

U.S. Patent No. 6,919,373

The '373 patent covered an osmotic delivery system with structural and operational characteristics intended to produce controlled release of methylphenidate. The claims addressed the relationship between the tablet's drug-containing compartments, delivery orifices, osmotic components, and release profile.

The Federal Circuit described the dispute as turning on whether the claimed formulation and delivery parameters would have been obvious in view of prior-art osmotic systems and methylphenidate references. The court affirmed the district court's obviousness analysis. Alza, 603 F.3d at 938-39, 944-46.

Earlier Concerta patents

Concerta was also associated with earlier Alza patents, including U.S. Patent No. 5,837,284. That patent was involved in separate Concerta litigation and had a different expiration profile from the '373 patent. The existence of other Concerta patents did not preserve the '373 patent after the Federal Circuit affirmed its invalidity.

A patent estate can contain multiple overlapping rights, including formulation, dosage-form, manufacturing, and method-of-use patents. Invalidity of one patent does not automatically invalidate the others. In this case, the appellate decision directly resolved the validity of the asserted '373 claims.

What did Impax's Paragraph IV certification challenge?

Impax filed an ANDA seeking approval to market a generic extended-release methylphenidate product. Its patent certification challenged Alza's listed patent under Paragraph IV of the Hatch-Waxman Act.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or would not be infringed by the proposed ANDA product. Alza responded by filing an infringement action in Delaware. The filing triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to the procedural rules applicable at the time.

The case therefore followed the standard Hatch-Waxman sequence:

1. Impax submitted an ANDA.
2. Impax provided a Paragraph IV notice.
3. Alza filed a patent infringement complaint.
4. FDA approval was stayed while the litigation proceeded.
5. The district court adjudicated validity and infringement issues.
6. The Federal Circuit reviewed the judgment.
7. The invalidity determination was affirmed.

The appellate opinion focused on validity rather than a later settlement-based launch arrangement.

Why did the Federal Circuit find the Concerta patent obvious?

The Federal Circuit affirmed the district court's conclusion that the asserted claims of the '373 patent were obvious. The analysis applied the familiar four-part framework:

• Scope and content of the prior art.
• Differences between the prior art and the claimed invention.
• Level of ordinary skill in the art.
• Objective evidence of nonobviousness.

The court treated the claimed delivery system as a combination of known osmotic-release technologies and known methylphenidate formulation concepts. The central question was whether the skilled artisan would have had reason to combine the relevant teachings and a reasonable expectation of success.

The decision rejected Alza's argument that the prior art would have discouraged the claimed approach. The court also found that the evidence did not establish sufficient unexpected results or other objective indicia to overcome the prior-art showing. Alza, 603 F.3d at 943-46.

Key legal holding

The appellate holding was that the district court did not clearly err in its underlying factual findings and correctly applied the obviousness standard. The Federal Circuit therefore affirmed the judgment against Alza.

The decision is significant for pharmaceutical patent analysis because it illustrates that a complex extended-release formulation may be vulnerable when its individual structural elements and operating parameters are drawn from established delivery technologies.

What was the final outcome of Alza v. Impax?

The final result was unfavorable to Alza:

Procedural event	Result
Delaware patent litigation	District court found the asserted patent claims invalid for obviousness
Federal Circuit appeal	Judgment affirmed
Patent status in the case	Asserted claims unenforceable as a practical barrier because they were invalid
Impax position	Successful validity challenge
Alza position	Lost the principal patent claim set at issue
Case status	Concluded after appellate judgment

The Federal Circuit decision was issued in 2010. The reported appellate disposition did not reinstate the patent or order a permanent injunction against Impax.

Did Alza and Impax settle the case?

The reported Federal Circuit decision was an adjudicated invalidity case, not a settlement-based resolution. The public appellate record identifies the outcome as affirmance of the district court's judgment.

No settlement agreement is material to the holding in Alza v. Impax. Any commercial arrangements involving Concerta or later generic distribution should be separated from the judicial determination that the asserted '373 claims were invalid.

What was the FDA and Orange Book significance?

The case was an FDA-regulated Hatch-Waxman dispute involving a small-molecule generic, not a biologic or biosimilar proceeding.

Orange Book status

The relevant FDA framework was the Orange Book listing of patents associated with the reference-listed drug, Concerta. A Paragraph IV challenge to an Orange Book-listed patent creates litigation risk for the ANDA applicant and may delay approval through the statutory 30-month stay.

The court's invalidity judgment reduced the enforceability of the asserted patent as a basis for blocking FDA approval. The case did not, by itself, determine the complete Orange Book status of every Concerta-related patent.

No biosimilar issue

Biosimilar provisions under the Public Health Service Act were not implicated. Concerta is a small-molecule drug regulated through the ANDA pathway under the Federal Food, Drug, and Cosmetic Act.

When did Concerta lose exclusivity after the Impax decision?

The litigation removed a major patent obstacle when the Federal Circuit affirmed invalidity in 2010. Actual generic entry depended on FDA approval, other applicable patents and exclusivities, manufacturing readiness, and any separate commercial arrangements.

Concerta's market exclusivity was not determined by the '373 patent alone. The product's commercial protection involved:

• FDA regulatory exclusivity, if applicable;
• Orange Book-listed patents;
• Earlier formulation and delivery patents;
• Pediatric exclusivity;
• Separate litigation involving other generic applicants; and
• Potential authorized-generic or licensing arrangements.

The invalidity decision materially reduced Alza's ability to use the '373 patent to delay Impax's product. It did not automatically eliminate every other legal or regulatory constraint affecting generic launch.

How strong was Alza's Concerta patent estate?

The Alza estate had meaningful technical breadth but faced validity risk when claims were drafted around combinations of known osmotic-release components and predictable release parameters.

Estate characteristic	Assessment
Technology	Controlled-release methylphenidate and osmotic delivery
Formulation coverage	Material, particularly for extended-release tablets
Method-of-use coverage	Less central to the reported Impax decision
Manufacturing coverage	Not the principal issue in the appellate opinion
Validity risk	High for the asserted '373 claims after the obviousness judgment
Litigation strength	Insufficient to preserve the asserted claims
Commercial impact	Reduced ability to delay a competing ANDA product

The decision does not establish that every Alza Concerta patent was weak. It establishes that the asserted claims of the '373 patent could not withstand the obviousness challenge presented by Impax.

What generic entry risks did Impax face?

Impax faced the standard risks associated with a Paragraph IV launch:

1. Patent injunction risk. Alza could have sought to block approval or commercial launch if the patent claims had survived.
2. Validity risk. The district court's obviousness ruling could have been reversed on appeal.
3. Infringement risk. Even if the patent were invalidated, different claims or other patents could have created separate exposure.
4. Regulatory timing risk. FDA approval remained distinct from the judicial patent result.
5. Commercial launch risk. A generic entrant could face price erosion, substitution uncertainty, and competition from other applicants.

The appellate affirmance substantially reduced the first two risks for the '373 patent. It did not provide blanket freedom to operate across all Concerta-related intellectual property.

Which companies challenged Concerta patents?

Concerta faced multiple generic challenges over time, including litigation involving Mylan and Impax. The relevant cases should not be treated as a single proceeding because they involved different defendants, patent claims, procedural postures, and outcomes.

The Impax case is distinct from Alza Corp. v. Mylan Laboratories, Inc., 464 F.3d 1286 (Fed. Cir. 2006). The Mylan decision addressed a separate Concerta patent dispute and is frequently cited in discussions of obviousness and controlled-release formulations. Its reasoning should not be substituted for the holding in the Impax case.

Did the case create manufacturing or formulation barriers?

The asserted patent concerned a formulation and delivery system rather than a simple active-ingredient composition. Extended-release products can present manufacturing barriers even after patent invalidity because generic manufacturers must reproduce:

• Drug-release kinetics;
• Tablet geometry and coating characteristics;
• Osmotic pressure behavior;
• Dose proportionality;
• Stability over shelf life;
• Dissolution profiles; and
• Bioequivalence under FDA requirements.

These technical requirements can preserve commercial differentiation after a patent loss. They do not, however, restore an invalid patent or independently prevent FDA approval if the ANDA satisfies regulatory standards.

What is the commercial impact of the Alza v. Impax ruling?

The decision weakened Alza's ability to protect Concerta sales through the '373 patent and improved Impax's position in pursuing generic approval and launch. The commercial consequences included potential:

• Earlier generic competition;
• Reduced brand pricing power;
• Lower market share for Concerta;
• Increased reimbursement substitution;
• Greater pressure on later generic entrants; and
• Reduced value of licensing leverage tied specifically to the invalidated claims.

The ruling did not establish a specific revenue loss in the reported opinions. Revenue exposure would depend on Concerta sales at the time, the timing of FDA approval, the number of competing generic applicants, and the treatment of other patents and regulatory exclusivities.

Key Takeaways

• Alza Corp. v. Impax Labs., No. 1:05-cv-00642, was a Hatch-Waxman dispute over generic extended-release methylphenidate.
• The principal patent was U.S. Patent No. 6,919,373.
• The district court found the asserted claims obvious.
• The Federal Circuit affirmed in 2010 in 603 F.3d 935.
• The case was resolved by judgment, not by a settlement holding reported in the appellate decision.
• The ruling removed a major patent barrier to Impax's generic Concerta product.
• The decision did not invalidate every patent associated with Concerta.
• The dispute involved an ANDA and Paragraph IV certification, not a biosimilar application.
• Formulation and manufacturing complexity remained separate technical and regulatory issues after the patent judgment.

FAQs About Alza Corporation v. Impax Laboratories

What was the patent number in Alza v. Impax?

The principal patent was U.S. Patent No. 6,919,373, directed to an osmotic extended-release methylphenidate delivery system.

What court decided Alza v. Impax?

The case began in the U.S. District Court for the District of Delaware and was reviewed by the U.S. Court of Appeals for the Federal Circuit.

Did Impax win the Concerta patent case?

Impax prevailed on the central validity issue. The Federal Circuit affirmed the judgment that the asserted claims were invalid for obviousness.

Was Concerta protected by a biologic patent?

No. Concerta is a small-molecule methylphenidate product. Its generic challenges proceeded under the ANDA and Hatch-Waxman framework.

Did invalidating the '373 patent eliminate all Concerta patent protection?

No. Concerta had a broader patent and exclusivity history. The ruling directly affected the asserted claims of the '373 patent and did not automatically dispose of other patents or regulatory protections.

References

1. Alza Corp. v. Impax Laboratories, Inc., 603 F.3d 935 (Fed. Cir. 2010).

2. Alza Corp. v. Mylan Laboratories, Inc., 464 F.3d 1286 (Fed. Cir. 2006).

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Patent and Trademark Office. (2002). U.S. Patent No. 6,919,373: Methylphenidate osmotic delivery system. U.S. Department of Commerce.

5. Hatch-Waxman Amendments, 21 U.S.C. § 355(j).